September 29, 2022
Specially Appointed Professor Kazuhisa Seki, Endowed Chairs of Silkworm Drug Discovery, Teikyo University Faculty of Faculty of Pharma-Science, is the principal investigator, and Hiroshi Hamamoto, Associate Professor, Medical Mycology Research Center, is the research co-investigator. Nonclinical Development Research Part 2” was adopted by the Japan Agency for Medical Research and Development (AMED) for the 2022 “Research Project for the Promotion of Development of Innovative Drugs for Emerging and Re-emerging Infectious Diseases (Fourth public offering)”. .
This study aims to verify the efficacy of the antibiotic lysocin E against MRSA, including vancomycin-resistant strains, and to clarify its therapeutic position against existing antibacterial drugs. It is carried out following the next open call for participants business.
In the fourth public offering project, we aim to examine vehicle formulations for drug GLP compliance tests, influence of various factors on the antibacterial activity of Lysocin E, and standardize the antibacterial activity measurement method of Lysocin E. Accomplishment of these research agendas is essential for the rapid initiation of human clinical trials of Lysocyn E.